Kiniksa Pharmaceuticals Current Ratio Over Time

Stocks . USA . 
Stock . Kiniksa Pharmaceuticals
KNSA Stock  USD 22.04  0.24  1.10%   
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Kiniksa Pharmaceuticals Performance and Kiniksa Pharmaceuticals Correlation.
For information on how to trade Kiniksa Stock refer to our How to Trade Kiniksa Stock guide.
  
As of November 26, 2024, Current Ratio is expected to decline to 4.12.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kiniksa Pharmaceuticals. If investors know Kiniksa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kiniksa Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
5.5
Earnings Share
(0.12)
Revenue Per Share
5.415
Quarterly Revenue Growth
0.674
Return On Assets
(0.03)
The market value of Kiniksa Pharmaceuticals is measured differently than its book value, which is the value of Kiniksa that is recorded on the company's balance sheet. Investors also form their own opinion of Kiniksa Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kiniksa Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kiniksa Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kiniksa Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Kiniksa Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kiniksa Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kiniksa Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Specify up to 10 symbols:
Apply

Cross Equities Current Ratio Analysis

Compare Kiniksa Pharmaceuticals and related stocks such as Nuvalent, Ventyx Biosciences, and Arcellx Current Ratio Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
201020112012201320142015201620172018201920202021202220232024
NUVL0.76210.76210.76210.76210.76210.76210.76210.76210.76210.76212.430633.074824.536322.82913.38
VTYX0.55310.55310.55310.55310.55310.55310.55310.55310.55310.55310.174621.413320.214411.87278.68
ACLX8.05568.05568.05568.05568.05568.05568.05568.05568.055612.52689.36397.59914.70726.05878.86
CGEM25.845225.845225.845225.845225.845225.845225.845225.845225.845239.671414.823925.248121.089517.066226.36
DAWN13.527513.527513.527513.527513.527513.527513.527513.527513.527513.527522.580733.425920.937312.717722.7
GPCR12.64212.64212.64212.64212.64212.64212.64212.64212.64212.64212.64212.61847.155219.143410.31
PHAT0.41220.41220.41220.41220.41220.41220.41220.41220.412268.19665.24769.85816.117810.248118.35
REPL11.285611.285611.285611.285611.285611.285611.285612.529614.262114.67533.254119.463117.519710.724213.37
NVCT2.41132.41132.41132.41132.41132.41132.41132.41132.41132.41132.41132.41133.29862.7472.26
LYRA12.717912.717912.717912.717912.717912.717912.717912.717912.71791.94315.5442.62626.96815.34888.27
KRON8.04048.04048.04048.04048.04048.04048.04048.04048.040434.595132.654225.506711.36987.23946.88
GOSS0.41960.41960.41960.41960.41960.41960.41960.351511.368611.085713.51428.32385.31955.94055.63
COGT12.494912.494912.494912.494912.494912.49497.98123.78723.24723.063918.704113.0379.86877.09427.05
LRMR16.982816.982816.982816.982816.982811.37113.230114.38719.11840.805810.89328.162311.27879.486111.63
KURA0.44570.08990.08010.05950.396617.184812.62349.434913.308615.394724.488623.259418.55712.26447.9
SPRO0.93260.93260.93260.93260.93260.93261.716110.7019.37193.07718.84798.45595.03983.53164.59
BOLT5.1185.1185.1185.1185.1185.1185.1185.1185.1184.14742.25158.86917.47245.16764.4
CHRS2.20382.20382.20380.85062.90431.49242.21634.46952.17543.25949.69468.01597.65131.43361.36

Kiniksa Pharmaceuticals and related stocks such as Nuvalent, Ventyx Biosciences, and Arcellx Current Ratio description

A liquidity ratio that measures a company's ability to pay short-term obligations or those due within one year. It compares a firm's current assets to its current liabilities.

My Equities

My Current Equities and Potential Positions

View AllNext
Kiniksa Pharmaceuticals
KNSA
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
LocationBermuda
ExchangeNASDAQ Exchange
USD 22.04
When determining whether Kiniksa Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kiniksa Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kiniksa Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kiniksa Pharmaceuticals Stock:
How To Invest In Kiniksa
Details
Is Kiniksa Stock a good investment?
Details
What is Kiniksa Pharmaceuticals' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out Kiniksa Pharmaceuticals Performance and Kiniksa Pharmaceuticals Correlation.
For information on how to trade Kiniksa Stock refer to our How to Trade Kiniksa Stock guide.
You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Kiniksa Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Overlap Analysis
View
Forecast Models
View
Price Shifting
View
Volatility Indicators
View
Value Movement
View
A focus of Kiniksa Pharmaceuticals technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Kiniksa Pharmaceuticals trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY